Literature DB >> 2275223

Pharmacokinetics of ranitidine in morbidly obese women.

R L Davis1, R W Quenzer, H P Bozigian, C W Warner.   

Abstract

The pharmacokinetics of a single dose of ranitidine 50 mg iv were determined in ten normal-weight and ten morbidly obese (greater than 90 percent ideal body weight) age-matched female subjects. No significant difference between normal and obese subjects was found in ranitidine peak serum concentration, volume of distribution, clearance, and elimination rate constant. Ranitidine volume of distribution and clearance were significantly smaller in the obese subjects per kilogram of total body weight (1.45 vs. 0.80 L/kg and 0.59 vs. 0.33 L/h/kg, respectively; p less than 0.001) but not when normalized to ideal body weight (1.65 vs. 1.45 L/kg and 0.68 vs. 0.59 L/h/kg). We conclude that obese patients receiving ranitidine therapy should be treated with standard dosages or dosages based on ideal body weight.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2275223     DOI: 10.1177/106002809002401101

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  7 in total

1.  Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Authors:  M Chen; A N Nafziger; G L Drusano; L Ma; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 2.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 3.  Body mass index and the efficacy of acid-mediating agents for GERD.

Authors:  Brian C Jacobson
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

4.  Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism.

Authors:  Y Caraco; E Zylber-Katz; E M Berry; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Hematological toxicity of carboplatin for gynecological cancer according to body mass index.

Authors:  Fernando Gutierrez; Guillermo Antonio Gonzalez-de-la-Fuente; Gloria Julia Nazco; Juana Oramas; Norberto Batista
Journal:  Eur J Clin Pharmacol       Date:  2016-06-10       Impact factor: 2.953

Review 6.  Dosing of medications in morbidly obese patients in the intensive care unit setting.

Authors:  Brian L Erstad
Journal:  Intensive Care Med       Date:  2003-11-19       Impact factor: 17.440

Review 7.  Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis.

Authors:  Brian L Erstad; Jeffrey F Barletta
Journal:  Crit Care       Date:  2021-02-23       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.